Disc Medicine develops investigational treatments for serious hematologic diseases by targeting red blood cell biology, including heme biosynthesis and iron homeostasis. News about IRON centers on its clinical-stage pipeline, including bitopertin for erythropoietic protoporphyria, DISC-0974 for anemia associated with myelofibrosis and chronic kidney disease, and DISC-3405 for polycythemia vera and other hematologic disorders.
Recurring updates include clinical trial progress, medical-meeting presentations, FDA communications, quarterly financial results, business updates, investor-conference participation, and leadership or organizational changes tied to the company’s development and commercialization planning.
Disc Medicine (NASDAQ:IRON) reported Q2 2025 financial results and significant pipeline progress. The company plans to submit an NDA for bitopertin in erythropoietic protoporphyria (EPP) under accelerated approval in October 2025, following a successful pre-NDA meeting.
Key pipeline developments include expected initial data from DISC-0974's Phase 2 study in myelofibrosis anemia and Phase 1b study in NDD-CKD anemia in Q4 2025. The company also initiated a Phase 2 study of DISC-3405 in polycythemia vera.
Financially, Disc ended Q2 with $650.0 million in cash, providing runway into 2028. Q2 net loss was $55.2 million, with R&D expenses at $46.3 million and SG&A expenses at $15.1 million.
Disc Medicine (NASDAQ:IRON) has received positive feedback from its pre-NDA meeting with the FDA regarding bitopertin, its treatment for Erythropoietic Protoporphyria (EPP). The company has confirmed plans to submit its New Drug Application (NDA) in October 2025 under the FDA's accelerated approval pathway.
CEO John Quisel expressed confidence in the alignment with the FDA regarding the submission's timing and content. The company is preparing for its first potential product launch, marking a significant milestone in bringing bitopertin to the EPP community.
Disc Medicine (NASDAQ:IRON) has appointed Nadim Ahmed to its Board of Directors. Ahmed, currently President and CEO of Cullinan Therapeutics, brings over 25 years of leadership experience in drug development and commercialization.
The appointment comes at a strategic time as Disc Medicine prepares for potential NDA filing and launch of bitopertin for EPP (erythropoietic protoporphyria). Ahmed's previous roles include President of Hematology at Bristol Myers Squibb and President of Global Hematology & Oncology at Celgene Corporation, where he oversaw multiple successful product launches.
Disc Medicine (NASDAQ:IRON), a clinical-stage biopharmaceutical company specializing in treatments for hematologic diseases, has announced its participation in two major investor conferences. The company's management will engage in fireside chats at the Jefferies Global Healthcare Conference on June 5th at 10:30 a.m. ET and the Goldman Sachs 46th Annual Global Healthcare Conference on June 9th at 1:20 p.m. ET. Both sessions will be accessible via live webcast through Disc Medicine's investor relations website, with archived replays available post-event.
Disc Medicine (NASDAQ:IRON), a clinical-stage biopharmaceutical company specializing in treatments for hematologic diseases, has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. The company's management will engage in a fireside chat on Tuesday, May 20th at 9:00 am ET. Investors can access the live webcast through Disc Medicine's investor relations website at ir.discmedicine.com, with an archived replay available after the event.
Disc Medicine (NASDAQ:IRON) announces a virtual KOL investor event on May 9, 2025, focusing on anemia of myelofibrosis (MF) and its treatment landscape. The webinar will feature leading experts including:
- Dr. Aaron Gerds from Cleveland Clinic
- Dr. Prithviraj Bose from MD Anderson Cancer Center
The event will cover MF anemia's epidemiology, pathogenesis, and patient impact. Disc's leadership will present clinical data for DISC-0974, including Phase 1b trial results from the 2024 ASH meeting and ongoing Phase 2 trial design. They will discuss the expected market opportunity and timeline for interim Phase 2 data readout in 2025.
The webinar starts at 1:00 PM ET / 10:00 AM PT, with a replay available for 90 days on Disc's website.
Disc Medicine (NASDAQ:IRON) reported its Q4 and full year 2024 financial results, highlighting significant progress across its pipeline. The company ended 2024 with $490 million in cash and secured additional funding through a January 2025 public offering, extending operations into 2028.
Key developments include plans for bitopertin NDA submission in H2 2025 for erythropoietic protoporphyria (EPP) through accelerated approval pathway, with the APOLLO confirmatory trial set to begin mid-2025. The company presented positive data from DISC-0974's Phase 1b trial in myelofibrosis anemia and non-dialysis-dependent chronic kidney disease patients.
Financial results show R&D expenses increased to $96.7 million in 2024 from $69.3 million in 2023, while net loss widened to $109.4 million from $76.4 million. SG&A expenses rose to $33.0 million from $21.9 million, reflecting increased headcount and commercialization preparation efforts.